Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific insider transaction rather than a financial performance report.
Material Changes
The material change disclosed is a transaction by Mr. S M Bicknell, a person discharging managerial responsibility. On July 8, 2013, he purchased 10 Ordinary Shares at a price of 1,735 pence per share. This purchase resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,735 pence per Ordinary Share on July 8, 2013.
- Confirm the identity and role of Mr. S M Bicknell as a person discharging managerial responsibility.
- Note that the transaction volume was minimal (10 shares) and driven by dividend reinvestment.